Voya Investment Management LLC Buys 21,640 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Voya Investment Management LLC raised its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 11.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 205,391 shares of the biotechnology company's stock after buying an additional 21,640 shares during the period. Voya Investment Management LLC owned about 0.32% of Blueprint Medicines worth $17,914,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of BPMC. Sanctuary Advisors LLC bought a new position in Blueprint Medicines in the 3rd quarter valued at $202,000. Synovus Financial Corp grew its stake in shares of Blueprint Medicines by 4.0% during the third quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company's stock worth $2,224,000 after purchasing an additional 922 shares during the period. Franklin Resources Inc. increased its stake in shares of Blueprint Medicines by 0.7% in the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after acquiring an additional 265 shares during the last quarter. Exome Asset Management LLC bought a new stake in Blueprint Medicines in the third quarter valued at approximately $3,395,000. Finally, Empirical Asset Management LLC acquired a new stake in Blueprint Medicines during the 4th quarter worth $2,348,000.

Insider Activity at Blueprint Medicines

In other news, insider Ariel Hurley sold 3,203 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the transaction, the insider now owns 18,270 shares in the company, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $95.02, for a total transaction of $216,075.48. Following the sale, the chief operating officer now owns 69,266 shares of the company's stock, valued at approximately $6,581,655.32. This trade represents a 3.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is owned by company insiders.

Blueprint Medicines Price Performance

Shares of NASDAQ BPMC traded up $5.39 during midday trading on Friday, reaching $104.64. 1,514,066 shares of the company were exchanged, compared to its average volume of 772,640. The stock's 50-day moving average price is $87.69 and its 200-day moving average price is $93.33. The stock has a market cap of $6.69 billion, a P/E ratio of -96.89 and a beta of 0.83. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a one year low of $73.04 and a one year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The firm had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The company's revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.40 EPS. On average, sell-side analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BPMC. JPMorgan Chase & Co. boosted their target price on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Blueprint Medicines in a research report on Tuesday, March 18th. They issued an "outperform" rating for the company. Piper Sandler increased their price target on Blueprint Medicines from $109.00 to $119.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. Jefferies Financial Group started coverage on Blueprint Medicines in a report on Monday, March 17th. They issued a "buy" rating and a $135.00 price objective for the company. Finally, JMP Securities reissued a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Blueprint Medicines presently has an average rating of "Moderate Buy" and a consensus target price of $124.53.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.